Medical Product Supply Chains: Understanding New Challenges and Opportunities
Biomedical product manufacturers are facing supply chain disruptions, ranging from ingredients to reagents to computer chips. At the same time, Congress and the executive branch are placing new obligations on medical product companies to oversee their supply chains while also creating new financial incentives for onshoring those chains through a variety of vehicles, including contracts, grants, cooperative agreements, OTAs, and others.
Our panelists used their collective decades of experience to provide insight into recent and pending legislative changes and the key federal agencies and programs related to pharma, device manufacturing and health IT companies. They also discussed the tools available to address these developments.